HGH Fragment 176-191
Aliases: Frag 176-191 · AOD9604 precursor
Last verified: 2026-09-23
The short version
The C-terminal fragment of growth hormone (amino acids 176–191) — the region responsible for lipolysis. Precursor of AOD-9604; used for fat loss without GH effects. Key fact: Human data are limited: small trials or case-series reports exist, without large randomized studies. Preclinical + early clinical work in the 1990s; development shifted to AOD-9604. Status: research chemical. Not approved; WADA-banned.
Identity & type
- Molecular type
- fragment
- Origin
- The C-terminal fragment of growth hormone (amino acids 176–191) — the region responsible for lipolysis.
Mechanism of action
Mediates hGH lipolysis in adipose tissue without activating the classical GH receptor/growth.
not confirmed in humans
Dosing & routes
Official / clinical context
No approved official document exists for HGH Fragment 176-191. Any protocols mentioned are to be read as information, not as a recommendation.
Regulator-approved labeling and published study designs — never a recommendation.
Community-reported practice
250–500 mcg SC 1–2× daily, usually morning/pre-workout fasted. Similar to AOD: accelerated fat loss with a caloric deficit is reported, but no strong standalone effect; product quality varies widely.
Unverified self-reports. Not medical advice. Not endorsement.
Expected effects (community)
Similar to AOD: accelerated fat loss with a caloric deficit is reported, but no strong standalone effect; product quality varies widely.
Protocol — official vs community
Official / label
No approved product. The fragment failed to outperform placebo in obesity trials.
Duration: —
Same failed-in-trials status as AOD-9604 (they overlap as fragments).
Community (anecdotal)
250–500 mcg SC daily, fasted, pre-cardio; some dose 2× daily.
- Cycle:
- 4–8 weeks.
- Break:
- 4 weeks.
The fasted-cardio framing gives it a ritual structure the trial data never earned.
Human evidence
Human data are limited: small trials or case-series reports exist, without large randomized studies. Preclinical + early clinical work in the 1990s; development shifted to AOD-9604.
Preclinical evidence
Preclinical + early clinical work in the 1990s; development shifted to AOD-9604.
Known risks
- Local reactions; rare headache.characterized
- No glucose/IGF-1 impact in limited data.characterized
- Unregulated injectable supply — sterility, purity and accurate dose not assuredtheoretical
Teal: characterized in clinical/labeling contexts. Amber: theoretical or reported outside controlled settings.
Unknowns & evidence gaps
- Long-term human safety
- Optimal dose and pharmacokinetics
Frequently asked questions
References
Systematic references are being expanded; verify sources directly before any decision.